Developing a vaccine against multiple psychoactive targets: A case study of heroin

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 8, 2011, Pages 865-875

  Stowe, G Neil ^a   Schlosburg, Joel E ^a   Vendruscolo, Leandro F ^a   Edwards, Scott ^a   Misra, Kaushik K ^a   Schulteis, Gery ^b   Zakhari, Joseph S ^a   Koob, George F ^a   Janda, Kim D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

6 acetyl morphine; Addiction; Drug dependence; Heroin; Immunoconjugate; Morphine; Therapy; Treatment

Indexed keywords

ACETYLCHOLINESTERASE; ANTIBODY CONJUGATE; BUPRENORPHINE; CARBOXYLESTERASE; CLONIDINE; DRUGS USED IN THE TREATMENT OF ADDICTION; HEROIN VACCINE; METHADONE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; NALTREXONE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; BLOOD BRAIN BARRIER; DRUG DEPENDENCE TREATMENT; DRUG DESIGN; HALF LIFE TIME; HEROIN DEPENDENCE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; INTRAVENOUS DRUG ABUSE; NONHUMAN; REVIEW; VACCINE PRODUCTION;

EID: 84857729350     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711799219316     Document Type: Review

References (102)

1. Wright, C.R.A.; XLIX. On the action of organic acids and their anhydrides on the natural alkaloids. Part I. J. Chem. Soc., 1874, 27, 1031-1043.
2. Dott, D.; Stockman, R. The chemistry and pharmacology of some of the morphine derivatives. Yearbook Pharm., 1888, 349-355.
3. Stockman, R.; Dott, D. Report on the pharmacology of morphine and its derivatives. Brit. Med. J., 1890, ii, 189-192.
4. von Mering, J. Physiological and therapeutic investigations on the action of some morphia derivatives. Merck Rep., 1898, 7, 5-13.
5. Sneader, W. Drug prototypes and their exploration. Chichester: Wiley, 1996, pp. 185-187.
6. Sneader, W. The discovery of aspirin. Pharm. J., 1997, 259, 614-617.
7. Sneader, W. The discovery of heroin. Lancet, 1998, 352, 1697-1699.
8. Klous, M.; Van den Brink, W.; van Ree, J.; Beijnen, J. Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients. Drug Alcohol Depend., 2005, 80, 283-295.
9. Bammer, G.; Dobler-Mikola, A.; Fleming, P.; Strang, J.; Uchtenhagen, A. The heroin prescribing debate: integrating science and politics. Science, 1999, 284, 1277-1278.
10. Mark, T.L.; Woody, G.E.; Juday, T.; Kleber, H.D. The economic costs of heroin addiction in the United States. Drug Alcohol Depend., 2001, 61, 195-206.
11. Nutt, D.; King, L.; Saulsbury, W.; Blakemore, C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet, 2007, 369, 1047-1053.
12. Programme U.N.O.D.C. World Drug Report. Oxford University Press, Oxford, UK, 1997.
13. Treatment admissions for injection drug abuse. The DASIS Report, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, June 21, 2002.
14. UNAIDS H.C. The Open Society & THe Canadian International Development Agency; The Warsaw Decleration: A Framework for Effective Action on HIV/AIDS and Injecting Drug Abuse. Second International Policy Dialogue on HIV/AIDS; Warsaw, Poland, November 12-14, 2003.
15. Aceijas, C.; Stimson, G.; Hickman, M.; Rhodes, T. Global overview of injection drug use and HIV infection among injection drug users. AIDS, 2004, 18, 2296-2303.
16. Platt, D.; Rowlett, J.; Spealman, R. Discriminative stimulus effects of intravenous heroin and its metabolites in rhesus monkeys: opioid and dopaminergic mechanisms. J. Pharmacol. Exp. Ther., 2001, 299, 760-767.
17. Comer, S.; Collins, E.; MacArthur, R.; Fischman, M. Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans. Psychopharmacology, 1999, 143, 327-338.
18. Jasinski, D.; Preston, K. Comparison of intravenously administered methadone, morphine and heroin. Drug Alcohol Depend., 1986, 17, 301-310.
19. Moreno, A.Y.; Azar, M.R.; Warren, N.A.; Dickerson, T.J.; Koob, G.F.; Janda, K.D. A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol. Pharm., 2010, 7(2), 431-441.
20. Carrera, M.; Ashley, J.; Parsons, L.; Wirsching, P.; Koob, G.; Janda, K. Suppression of psychoactive effects of cocaine by active immunization. Nature, 1995, 378, 727-730.
21. Cunningham, K.; Lakoski, J. The interaction of cocaine with serotonin dorsal raphe neurons. Single-unit extracellular recording studies. Neuropsychopharmacology, 1990, 3, 41-50.
22. Barr, A.; Panenka, W.; MacEwan, W.; Thornton, A.; Lang, D.; Honer, W.; Lecomte, T. The need for speed: an update on methamphetamine addiction. J. Psychiatry Neurosci., 2006, 31(5), 301-313.
23. Moreno, A.; Mayorov, A.; Janda, K. Impact of Distinct Structures for the Development of a Methamphetamine Vaccine. J. Am. Chem. Soc., 2011, 133(17), 6587-6595.
24. Treweek, J.B.; Dickerson, T.J.; Janda, K.D. Drugs of abuse that mediate advanced glycation end product formation: a chemical link to disease pathology. Acc. Chem. Res., 2009, 42(5), 659-669.
25. Umans, J.; Inturrisi, C. Pharmacodynamics of subcutaneously administered diacetylmorphine, 6-acetylmorphine and morphine in mice. J. Pharmacol. Exp. Ther., 1981, 218, 409-415.
26. Inturrisi, C.; Schultz, M.; Shin, S.; Umans, J.; Angel, L.; Simon, E. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci., 1983, 33, 773-776.
27. Selley, D.; Cao, C.; Sexton, T.; Schwegel, J.; Martin, T.; Childers, S. Mu-opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochem. Pharmacol., 2001, 62, 447-455.
28. Salmon, A.; Zafrir, G.; Avissar, Y.; Soreq, H. Human erythrocyte but not brain acetylcholinesterase hydrolyses heroin to morphine. Clin. Exp. Pharmacol. Phys., 1999, 26, 596-600.
29. Lockridge, O.; Mottershaw-Jackson, N.; Eckerson, H.; La, D.B. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. J. Pharmacol. Exp. Ther., 1980, 215(1), 1-8.
30. Redinbo, M.; Bencharit, S.; Potter, P. Human carboxylesterase 1: from drug metabolism to drug discover. Biochem. Soc. Trans., 2003, 31, 620-624.
31. Kamendulis, L.; Brzezinski, M.; Pindel, E.; Bosron, W.; Dean, R. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J. Pharmacol. Exp. Ther., 1996, 279, 713-717.
32. Rook, E.; van Ree, J.; van den Brink, W.; Hillebrand, M.; Huitema, A.; Hendriks, V.; Beijnen, J. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin by intravenous or by inhalation route in opioid-dependent patients. Basic Clin. Pharmacol. Toxicol., 2006, 98, 86-96.
33. Kuo, C.K.; Hanioka, N.; Hoshikawa, Y.; Oguri, K.; Yoshimura, H. Species difference of site-selective glucuronidation of morphine. J. PharmacobioDyn., 1991, 14, 187-193.
34. Aasmundstad, T.; Ripel, A.; Bodd, E.; Bjorneboe, A.; Morland, J. Different biotransformation of morphine in isolated liver cells from guinea pig and rat. Biochem. Pharmacol., 1993, 46(6), 961-968.
35. Baselt, R.; Cravey, R. Dispostion of Toxic Drugs and Chemicals in Man. Yearbook Medical Publishers, Chicago, IL, 1989.
36. Oldendorf, W.; Hyman, S.; Braun, L.; Oldendorf, S. Blood-brain barrier: penetration of morphine, codeine, heroin and methadone after carotid injection. Science, 1972, 178, 984-987.
37. Herz, A.; Teschemacher, H. Activities and sites of antinociceptive action of morphine-like analgesics. Adv. Drug Res., 1971, 6, 79-119.
38. Kosten, T.; Beigel, D. Therapeutic vaccines for substance dependence. Expert Rev. Vaccines, 2002, 1, 363-371.
39. Kantak, K. Anti-cocaine vaccines: antibody protection against relapse. Expert Opin. Pharmacother., 2003, 4, 213-218.
40. Anton, B.; Salazar, A.; Flores, A.; Matus, M.; Marin, R.; Hernandez, J.; Leff, P. Vaccines against heroin/morphine and its use as effective medication for preventing relapse to opiate addiction behaviors. Hum. Vaccin., 2009, 5(4), 214-229.
41. Fowler, J.; Volkow, N.; Wang, G.; Gatley, S.; Logan, J. Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl. Med. Biol., 2001, 28, 561-572.
42. Gatley, S.; Volkow, N.; Gifford, A.; Fowler, J.; Dewey, S.; Ding, Y.; Logan, J. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology, 1999, 146, 93-100.
43. Volkow, N.; Wang, G.; Fischman, M.; Foltin, R.; Fowler, J.; Franceschi, D.; Franceschi, M.; Logan, J.; Gatley, S.; Wong, C.; Ding, Y.; Hitzemann, R.; Pappas, N. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci., 2000, 67, 1507-1515.
44. Way, E.; Kemp, J.; Young, J.; Grasseti, D. The pharmacologic effects of heroin in relationship to its rate of biotransformation. J. Pharmacol. Exp. Ther., 1960, 129, 144-154.
45. Andersen, J.; Ripel, A.; Boix, F.; Normann, P.; Morland, J. Increased locomotor activity induced by heroin in mice: pharmacokinetic demonstration of heroin acting as a prodrug for the mediator 6-monoacetylmorphine in vivo. J. Pharmacol. Exp. Ther., 2008, 331, 153-161.
46. Karinen, R.; Andersen, J.; Ripel, A.; Hasvold, I.; Hopen, A.; Morland, J.; Christophersen, A. Determination of heroin and its main metabolites in small sample volumes of whole blood and brain tissue by reversed-phase liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol., 2009, 33, 345-350.
47. Frances, B.; Gout, R.; Monsarrat, B.; Cros, J.; Zajac, J. Further evidence that morphine-6-beta-glucuronide is a more potent opioid agonist than morphine. J. Pharmacol. Exp. Ther., 1992, 262, 25-31.
48. Bickel, U.; Schumacher, O.; Kang, Y.; Voigt, K. Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. J. Pharmacol. Exp. Ther., 1996, 278, 107-113.
49. Wu, D.; Kang, Y.; Bickel, U.; Pardridge, W. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metab. Disp., 1997, 25(6), 768-771.
50. Aasmundstad, T.; Morland, J.; Paulsen, R. Distribution of morphine-6-glucuronide and morphine across the blood-brain barrier of awake, freely moving rats investigated by in vivo microdialysis sampling. J. Pharmacol. Exp. Ther., 1995, 275, 435-441.
51. Lotsch, J.; Kobal, G.; Stockmann, A.; Brune, K.; Geisslenger, G. Lack of analgesic activity of morphine-6-glucuronide after shortterm intravenous administration in healthy volunteers. Anesthesiology, 1997, 87, 1348-1358.
52. Motamed, C.; Mazoit, X.; Ghanouchi, K.; Guirimand, F.; Abhay, K.; Lieutaud, T.; Bensaid, S.; Fernandez, C.; Duvaldstein, P. Premptive intravenous morphine-6-glucuronide is ineffective for postoperative pain relief. Anesthesiology, 2000, 92, 355-360.
53. Diagnostic and Statistical Manual of Mental Disorders [DSM]. American Psychiatric Association, 2000.
54. Koob, G.; Le Moal, M. Drug abuse: hedonic homeostatic dysregulation. Science, 1997, 278, 52-58.
55. Nestler, E. From neurobiology to treatment: progress against addiction. Nat. Neurosci., 2002, 5(Suppl), 1076-1079.
56. Rounsaville, B.; Kosten, T.; Kleber, H. Sucess and failure at outpatient opioid detoxification: evaluating the process of clonidine-and methadone-assisted withdrawal J. Nerv. Ment. Dis., 1996, 173, 103-110.
57. Mattick, R.; Hall, W. Are detoxification programmes effective? Lancet, 1996, 347, 97-100.
58. Langendam, M.; van Haastrecht, H.; van Brussel, G.; Anneke, H.; van Den Hoek, A.; Coutinho, R.; van Ameijden, E. Differentiation in the Amsterdam methadone dispensing circuit: determinants of methadone dosage and site of methadone prescription. Addiction, 1998, 93, 61-72.
59. Termorshuizen, F.; Krol, A.; Prins, M.; van Ameijden, E. Longterm outcome of chronic drug use: the Amsterdam cohort study among drug users. Am. J. Epidemiol., 2005, 161, 271-279.
60. Dole, V.; Nyswander, M.; Kreek, M. Narcotic Blockade. Arch. Intern. Med., 1966, 118, 304-309.
61. Ra, R.; Yarmolinsky, A. Federal Regulation of Methadone Treatment. Institute of Medicine, National Acadamy Press, Washington, D.C., 1995, p. 77.
62. Center for Substance Abuse Treatment. Emerging issues in the use of methadone. Substance Abuse Treatment Advisory HHS Pub No (SMA) 09-4368, 2009, 8(1).
63. Tawil, O.; Verster, A.; O'Reilly, K. Enabling approaches for HIV/AIDS prevention: can we modify the environment and minimize the risk? AIDS, 1995, 9, 1299-1306.
64. Gillies, P.; Tolley, K.; Wostenholme, J. Is AIDS a disease of poverty? AIDS Care, 1996, 8, 351-363.
65. Cornish, J.; Metzger, D.; Woody, G.; Wilson, D.; McLellan, A.; Vandergrift, B.; O'Brien, C. Naltrexone pharmacotherapy for opiod dependent federal probationers. J. Subs. Abuse Treat., 1997, 14, 529-534.
66. Bradbury, M.; Lightman, S. The blood-brain interface. Eye, 1990, 4, 249-254.
67. Moreno, A.; Janda, K. Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol. Biochem. Behav., 2009, 92, 199-205.
68. Kosten, T.; Owens, M. Immunotherapy for the treatment of drug abuse. Pharmacol. Ther., 2005, 76-85.
69. Maurer, P.; Jennings, G.; Willers, J.; Rohner, F.; Lindman, Y.; Roubicek, K.; Renner, W.; Muller, P.; Bachmann, M. A therapeutic vaccine for nicotine dependence: preclinical efficacy and Phase I safety and immunogenicity. Eur. J. Immunol., 2005, 35(7), 2031-2040.
70. Carrera, M.; Ashley, J.; Wirsching, P.; Koob, G.; Janda, K. A second-generation vacine suppresses psychoactive effects of cocaine in the rat. Proc. Natl. Acad. Sci. USA, 2001, 98, 1988-1992.
71. Pentel, P.; Malin, D.; Ennifar, S.; Hieda, Y.; Keyler, D.; Lake, J.; Milstein, J.; Basham, L.; Coy, R.; Moon, J.; Naso, R.; Fattom, A. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav., 2000, 65(1), 191-198.
72. Spector, S.; Parker, C. Morphine: Radioimmunoassay. Science, 1970, 168, 1347-1348.
73. Wainer, B.; Fitch, F.; Fried, J.; Rothber, R. Measurement of the specificities of antibodies to morphine-6-succinyl BSA by competitive inhibition of C-morphine binding. J. Immunol., 1973, 110, 667-673.
74. Simon, E.; Dole, W.; Hiller, J. Coupling of a new, active morphine derivative to sepharose for affinity chromatography. Proc. Natl. Acad. Sci. USA, 1972, 69(7), 1835-1837.
75. Koida, M.; Takahashi, M.; Muraoka, S.; Kaneto, H. Antibodies to BSA conjugates of morphine derivatives: strict dependency of the immunological specificity on the hapten structure. Jpn. J. Pharmacol., 1974, 24, 165-167.
76. Spector, S.; Berkowitz, B.; Flynn, E.; Peskar, B. Antibodies to morphine, barbiturates and serotonin. Pharm. Rev., 1973, 25, 281-291.
77. Gross, S.; Grant, J.; Wong, R.; Schuster, R.; Lomax, P.; Campbell, D. Critical antigenic determinant for production of antibody to distinguish morphine from heroin, codeine and dextromorphan. Immunochemistry, 1974, 11, 453-456.
78. Koida, M.; Takahashi, M.; Kaneto, H. The morphine-3-glucuronide directed antibody: its immunological specificity and possible use for radioimmunoassay of morphine in urine. Jpn. J. Pharmacol., 1974, 24, 707-714.
79. Morris, B.; Robinson, J.; Piall, E.; Aherne, G.; Marks, V. Development of a radioimmunoassay for morphine having minimal cross-reactivity with codeine. J. Endocrin., 1975, 64(1), 6P-7P.
80. Findlay, J.; Butz, R.; Jones, E. Relationships between immunogen structure and antisera specificity in the narcotic alkaloid series. Clin. Chem., 1981, 27(9), 1524-2535.
81. Usagawa, T.; Itoh, Y.; Hifumi, E.; Takeyasu, A.; Nakahara, Y.; Uda, T. Characterization of morphine-specific monoclonal antibodies showing minimal cross-reactivity with codeine. J. Immunol. Meth., 1993, 157, 143-148.
82. Beike, J.; Blaschke, G.; Mertz, A.; Kohler, H.; Brinkmann, B. A specific immunoassay for the determination of morphine and its glucuronides in human blood. Int. J. Legal Med., 1998, 112, 8-14.
83. Bonese, K.; Wainer, B.; Fitch, F.; Rothberg R. Changes in selfadministration by a rhesus monkey after morphine immunization. Nature, 1974, 252(5485), 708-710.
84. Anton, B.; Leff, P. A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine, 2006, 24(16), 3232-3240.
85. Ino, A.; Dickerson, T.; Janda, K. Positional effects in haptens for cocaine immunopharmacotherapy. Bioorg. Med. Chem. Lett., 2007, 17(15), 4280-4283.
86. Matsushita, M.; Hoffman, T.; Ashley, J.; Wirsching, P.; Lerner, R.; Janda, K. Cocaine catalytic antibodies: the importance of linker effects. Bioorg. Med. Chem., 2001, 11, 87-90.
87. Stowe, G.; Vendruscolo, L.; Edwards, S.; Schlosburg, J.; Misra, K.; Schulteis, G.; Mayorov, A.; Zakhari, J.; Koob, G.; Janda, K. A vaccine strategy that induces protective immunity against heroin. J. Med. Chem., 2011, 54, 5195-5204.
88. Skibinski, D.; O'Hagan, D.; Adjuvants. In: Vaccine Design: Innovative Approaches and Novel Strategies; Rappuoli, R.; Bagnoli, F., ed.; Caister Academic Press, Norfolk, UK, 2011, pp. 139-169.
89. Marrack, P.; McKee, A.; Munks, M. Towards an understanding of the adjuvant action of aluminum. Nat. Rev., 2009, 9, 287-293.
90. O'Hagan, D.; Valiante, N. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Disc., 2003, 2(9), 727-735.
91. HogenEsch, H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine, 2002, 20, S34-S39.
92. Glenny, A.T.; Pope, C.G.; Waddington, H.; Wallace, U. The antigenic value of toxiod preciptated by potassium alum. J. Pathol. Bacteriol., 1926, 29, 31-40.
93. Glenny, A.; Buttle, A.; Stevens, M. Rate of disappearance of diphtheria toxioid injected into rabbits and guinea pigs: toxoid precipitated with alum. J. Pathol. Bacteriol., 1931, 34, 267-275.
94. Harrison, W. Some observations on the use of alum precipitated diphtheria toxoid. Am. J. Public Health, 1935, 25, 298-300.
95. Hem, S.; HogenEsch, H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev. Vaccines, 2007, 6(5), 685-697.
96. Gupta, R.; Chang, A.; Griffin, P.; Rivera, R.; Siber, G. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine, 1996, 14, 1412-1416.
97. MacLean, D.; Robertson, J.; Jay, M. Monitoring the retention of a protein antigen in complete Freunds' adjuvant, alum and pluronic R-127 gel formulations by x-ray fluorescence. Pharm. Dev. Technol., 2001, 6, 241-246.
98. Vendruscolo, L.F.; Schlosburg, J.E.; Misra, K.K.; Chen, S.; Greenwell, T.N.; Koob, G.F. Escalation patterns of varying periods of heroin access. Pharmacol. Biochem. Behav., 2011, 98(4), 570-574.
99. Jencks, W. Catalysis in chemistry and enzymology. Dover, New York, 1967, 163-182.
100. Sakuri, M.; Wirsching, P.; Janda, K. Design and synthesis of a cocaine-diamide hapten for vaccine development. Tetrahedron Lett., 1996, 37, 5479-5482.
101. Tomei, E.; Renaud, F.L. Effect of morphine on Fc-mediated phagocytosis by murin macrophages in vitro. J. Neuroimmun., 1997, 74, 111-116.
102. Roy, S.; Cain, K.J.; Chapin, R.B.; Charboneau, R.G.; Barke, R.A. Morpine modulates NFkB activation in macrophages. Biochem. Biophys. Res. Comm., 1998, 245, 392-396.